2008 Annual Conference Supporters

Presenting Supporter:
Amgen
Bristol-Myers Squibb and ImClone Systems Incorporated
Genentech BioOncology
sanofi-aventis, U.S.

Gold Supporter:
AstraZeneca and Abraxis BioScience
Eli Lilly and Company
Merck Oncology
Novartis Oncology
Ortho Biotech
Pfizer Inc.
Schering-Plough Corporation
Wyeth

Silver Supporter:
Bayer HealthCare Pharmaceutical, Inc. and Onyx Pharmaceuticals, Inc.
Celgene Corporation
GlaxoSmithKline Oncology
Millennium Pharmaceuticals, Inc.
Roche

Friend:
Cephalon Oncology
Eisai Inc
MGI PHARMA, INC.
Pharmion Corporation
Reed Medical Education
Takeda Pharmaceuticals North America

Supporter:
Abbott Laboratories
Ariad Pharmaceuticals, Inc.
Biogen Idec
TAP

Other Support:
Fellows:
Amgen
Bristol-Myers Squibb and ImClone Systems Incorporated
Eli Lilly and Company
Millennium Pharmaceuticals, Inc.
Novartis Oncology
Pfizer Inc.
sanofi-aventis, U.S.

Fellows Award:
Amgen
Eli Lilly and Company
Millennium Pharmaceuticals, Inc.
Novartis Oncology
Pfizer Inc.
sanofi-aventis, U.S.
Wyeth

Nurses:
Amgen
Eisai Inc.
Eli Lilly and Company
Endo Pharmaceuticals
Merck Oncology
MGI PHARMA, INC.
Novartis Oncology
Pfizer Inc.

Pharmacy:
Amgen
AstraZeneca and Abraxis BioScience

Exhibitor Offerings:
Complimentary Binder Shipping Station - Genentech BioOncology
Custom Key Card - Cephalon
Wireless Zone / Internet Café - Eli Lilly and Company

Satellite Symposia
Breakfast Symposia:
“Treating Lung Cancer in Women” – Eli Lilly and Company
"Future Directions in the Treatment of Lung Cancer” – AstraZeneca
“Management of Opioid-Induced Side Effects” – Wyeth

Lunch Symposia:
“Use of Biomarkers in the Management of Colorectal Cancer” – Bristol-Myers Squibb and ImClone Systems Incorporated
"New Advances in the Treatment of Chronic Myelogenous Leukemia" – Novartis Oncology
"Targeted Therapies in Advanced Renal Cell Carcinoma” – Wyeth

Dinner Symposia:
"Management of Elderly Cancer Patients with Impaired Kidney Function” – Millennium Pharmaceuticals, Inc.
“Advances in the Management of Taxane-Resistant Breast Cancer Patients” – Bristol-Myers Squibb

NCCN appreciates that these supporting companies recognize NCCN’s need for autonomy in the development of the content of NCCN programs and resources. All NCCN content is produced completely independently.

Last Updated:1/22/2008